Tratamiento de la toxicidad cutánea secundaria al tratamiento radioterápico con una crema basada en sH oligopeptide-1 (epidermal growth factor-egf)un estudio piloto

  1. Seral-Gajón, Antonio Luis
  2. Carreras-Sospedra, Ana
  3. López-Jimeno, Carla
  4. Hijano- Berberia, Vanessa
  5. Viedma-Pastor, Mariano
  6. Russo,Gabriella
  7. Mayayo-Falo, Teo
  8. Martínez-Martínez, Fernando
  9. Fernández-Rodríguez, María
Revista:
Actualidad médica

ISSN: 0365-7965

Año de publicación: 2018

Tomo: 103

Número: 804

Páginas: 76-81

Tipo: Artículo

DOI: 10.15568/AM.2018.804.OR04 DIALNET GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: Actualidad médica

Objetivos de desarrollo sostenible

Resumen

La dermatitis aguda es muy frecuente en pacientes tratados por neoplasias de mama, cabeza, cuello y tumores cutáneos, debido a las elevadas dosis de radiación administradas, y puede afectar hasta el 95% de los pacientes. Tales efectos pueden disminuir la calidad de vida de los pacientes. El objetivo del presente estudio es valorar como medida profiláctica frente a la radiodermatitis, la eficacia de Radio Cream® de Inves Biofarm. Se reclutaron 20 pacientes que precisaban tratamiento radioterápico, con dosis entre 42,72 Gy y 70 Gy. La crema se aplicó durante todo periodo de tratamiento, 2 veces al día. Se evaluó la toxicidad de la piel mediante los criterios del National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), que evalúan lesiones agudas por la radiación en una escala de 0 a 4. Al finalizar el tratamiento se aprecia un porcentaje del 5%, 65% y 30% para la toxicidad grado 0, 1, 2 respectivamente, sin observarse grado 3 ni 4. En el momento de finalizar el tratamiento, un 70% no presentaban prurito y el 30% grado 1. La puntuación media de los pacientes fue de 8,38 en escala de 1 a 10. Podemos estimar que la crema Radio Cream® se ha mostrado como una opción válida para la prevención de radiodermatitis. Puede impedir o retrasar la aparición de la toxicidad cutánea, contribuyendo al mantenimiento de la calidad de vida de los pacientes y permitir completar el tratamiento radioterápico a las dosis prescritas.

Referencias bibliográficas

  • Singh M, Alavi A, Wong R, Akita S. Radiodermatitis: A Review of Our Current Understanding. Am J Clin Dermatol 2016 Jun;17(3):277-92.
  • Hickok JT, Morrow GR, Roscoe JA, Mustian K, Okunieff P. Occurrence, severity, and longitudinal course of twelve common symptoms in 1129 consecutive patients during radiotherapy for cancer. J Pain Symptom Manage 2005 Nov;30(5):433-42.
  • Hymes SR, Strom EA, Fife C. Radiation dermatitis: clinical presentation, pathophysiology, and treatment 2006. J Am Acad Dermatol 2006 Jan;54(1):28-46.
  • Chan RJ, Larsen E, Chan P. Re-examining the evidence in radiation dermatitis management literature: an overview and a critical appraisal of systematic reviews. Int J Radiat Oncol Biol Phys 2012 Nov 1;84(3):e357-e362.
  • Lee J, Park W, Choi DH, Huh SJ, Kim IR, Kang D, et al. Patientreported symptoms of radiation dermatitis during breast cancer radiotherapy: a pilot study. Qual Life Res 2017 Jul;26(7):1713-9.
  • Wong RK, Bensadoun RJ, Boers-Doets CB, Bryce J, Chan A, Epstein JB, et al. Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group. Support Care Cancer 2013 Oct;21(10):2933-48.
  • McQuestion M. Evidence-based skin care management in radiation therapy. Semin Oncol Nurs 2006 Aug;22(3):163-73.
  • Kumar S, Juresic E, Barton M, Shafiq J. Management of skin toxicity during radiation therapy: a review of the evidence. J Med Imaging Radiat Oncol 2010 Jun;54(3):264-79.
  • Cornejo Uribe R. Epidermal Growth Factor and Mammary Epithelial Differentiation. Int.J.Morphol [29(3)], 821-824. 9-9-2011.
  • Carpenter G, Cohen S. Epidermal growth factor. Annu Rev Biochem 1979;48:193-216.
  • Inves-Biofarm. INFORME DE SEGURIDAD. sh-oligopeptide-1. 1-5.
  • Vaughn AR, Clark AK, Sivamani RK, Shi VY. Natural Oils for Skin-Barrier Repair: Ancient Compounds Now Backed by Modern Science. Am J Clin Dermatol 2018 Feb;19(1):103-17.
  • Rouvrais C, Bacqueville D, Bogdanowicz P, Haure MJ, Duprat L, Coutanceau C, et al. A new dermocosmetic containing retinaldehyde, delta-tocopherol glucoside and glycylglycine oleamide for managing naturally aged skin: results from in vitro to clinical studies. Clin Cosmet Investig Dermatol 2017;10:35-42.
  • Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995 Mar 30;31(5):1341-6.
  • Porock D, Kristjanson L. Skin reactions during radiotherapy for breast cancer: the use and impact of topical agents and dressings. Eur J Cancer Care (Engl ) 1999 Sep;8(3):143-53.
  • Denham JW, Hauer-Jensen M. The radiotherapeutic injury--a complex 'wound'. Radiother Oncol 2002 May;63(2):129-45.
  • Olascoaga A, Vilar-Compte D, Poitevin-Chacon A, ContrerasRuiz J. Wound healing in radiated skin: pathophysiology and treatment options. Int Wound J 2008 Jun;5(2):246-57.
  • Haubner F, Ohmann E, Pohl F, Strutz J, Gassner HG. Wound healing after radiation therapy: review of the literature. Radiat Oncol 2012 Sep 24;7:162.
  • Lee SW, Jung KI, Kim YW, Jung HD, Kim HS, Hong JP. Effect of epidermal growth factor against radiotherapy-induced oral mucositis in rats. Int J Radiat Oncol Biol Phys 2007 Mar 15;67(4):1172-8.
  • Wu HG, Song SY, Kim YS, Oh YT, Lee CG, Keum KC, et al. Therapeutic effect of recombinant human epidermal growth factor (RhEGF) on mucositis in patients undergoing radiotherapy, with or without chemotherapy, for head and neck cancer: a double-blind placebo-controlled prospective phase 2 multi-institutional clinical trial. Cancer 2009 Aug 15;115(16):3699-708.
  • Ryu SH, Kim YH, Lee SW, Hong JP. The preventive effect of recombinant human growth factor (rhEGF) on the recurrence of radiodermatitis. J Radiat Res 2010;51(5):511-7.
  • Zhang Y, Zhang S, Shao X. Topical agent therapy for prevention and treatment of radiodermatitis: a metaanalysis. Support Care Cancer 2013 Apr;21(4):1025-31.
  • Schmuth M, Wimmer MA, Hofer S, Sztankay A, Weinlich G, Linder DM, et al. Topical corticosteroid therapy for acute radiation dermatitis: a prospective, randomized, doubleblind study. Br J Dermatol 2002 Jun;146(6):983-91.
  • Pommier P, Gomez F, Sunyach MP, D'Hombres A, Carrie C, Montbarbon X. Phase III randomized trial of Calendula officinalis compared with trolamine for the prevention of acute dermatitis during irradiation for breast cancer. J Clin Oncol 2004 Apr 15;22(8):1447-53.
  • Niazi TM, Vuong T, Azoulay L, Marijnen C, Bujko K, Nasr E, et al. Silver clear nylon dressing is effective in preventing radiation-induced dermatitis in patients with lower gastrointestinal cancer: results from a phase III study. Int J Radiat Oncol Biol Phys 2012 Nov 1;84(3):e305-e310.
  • Kang HC, Ahn SD, Choi DH, Kang MK, Chung WK, Wu HG. The safety and efficacy of EGF-based cream for the prevention of radiotherapy-induced skin injury: results from a multicenter observational study. Radiat Oncol J 2014 Sep;32(3):156-62.
  • Choi J, Moon SY, Hong JP, Song JY, Oh KT, Lee SW. Epidermal growth factor induces cell death in the absence of overexpressed epidermal growth factor receptor and ErbB2 in various human cancer cell lines. Cancer Invest 2010 Jun;28(5):505-14.
  • Geissler C, Hambek M, Eckardt A, Arnoldner C, Diensthuber M, Stover T, et al. The role of recombinant epidermal growth factor and serotonin in the stimulation of tumor growth in a SCCHN xenograft model. Oncol Rep 2012 Sep;28(3):785-90.
  • Ginsburg E, Vonderhaar BK. Epidermal growth factor stimulates the growth of A431 tumors in athymic mice. Cancer Lett 1985 Sep 15;28(2):143-50.
  • Berlanga-Acosta J, Gavilondo-Cowley J, Lopez-Saura P, Gonzalez-Lopez T, Castro-Santana MD, Lopez-Mola E, et al. Epidermal growth factor in clinical practice – a review of its biological actions, clinical indications and safety implications. Int Wound J 2009 Oct;6(5):331-46.
Fuente de los datos: Dialnet